Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Olaparib (Lynparza) Resubmission for Ovarian Cancer
(Pending Submission as of February 15, 2017)

Rituximab (Rituxan) for Acute Lymphoblastic Leukemia
(Open for Input on Submission until February 28, 2017)

Daratumumab (Darzalex) for Multiple Myeloma (second-line)
(Pending Submission as of February 3, 2017)

Vandetanib (Caprelsa) for Medullary Thyroid Cancer
(Open for Feedback on Recommendation until February 16, 2017)

Carfilzomib (Kyprolis) for Multiple Myeloma (relapsed)
(Open for Feedback on Recommendation until February 16, 2017)

Blinatumomab (Blincyto) for Pediatric Acute Lymphoblastic Leukemia 
(Pending Submission as of January 26, 2017)

Blinatumomab (Blincyto) for Adult Acute Lymphoblastic Leukemia (Resubmission)
(Pending Submission as of September 28, 2016)

 

 

Find a Drug Review